ArcFlex Sheath in TAVR Trial

Inclusion Criteria: * Judged by a professional cardiologist to require TAVR surgery * NYHA ≥ II grade * Evaluated by the cardiac team, the peripheral vascular approach is suitable for performing the surgery via the femoral route * Expected lifespan is greater than 1 year (5) Patients who can understand the purpose of the trial, voluntarily participate, sign the informed consent form, and are willing to undergo relevant examinations and clinical follow-ups. Exclusion Criteria: * Presence of other valvular diseases requiring concurrent intervention. * Anatomical characteristics unsuitable for transcatheter valve implantation. * Severe mitral stenosis due to organic causes requiring surgical valve replacement or repair. * Hypertrophic obstructive cardiomyopathy (unexplained myocardial hypertrophy \>1.5 cm). * Acute myocardial infarction within the past 30 days. * Intracardiac mass, thrombus, or vegetation indicated by echocardiography. * Active infective endocarditis or any other active infection. * Intolerance to tolerate anticoagulant or antiplatelet therapy. * Coagulopathy or refusal to receive blood transfusion therapy. * Known allergy to device materials or contrast agents. * Acute peptic ulcer or gastrointestinal bleeding within the past 3 months. * Stroke or transient ischemic attack (TIA) within the past 3 months. * Requirement for emergency surgical treatment for any reason. * Expected life expectancy of less than 12 months due to non-cardiac causes. * Severe disabling dementia or inability to perform activities of daily living. * Participation in other clinical trials of drugs or medical devices prior to enrollment and not yet reached the primary endpoint of that study.